RecruitingPHASE2, PHASE3NCT06513533
Dimethyl Fumarate in Adrenomyeloneuropathy
Studying Adrenomyeloneuropathy
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Pujol, Aurora, M.D.
- Principal Investigator
- Carlos Casasnovas, MD, PhDBellvitge University Hospital
- Intervention
- Placebo(other)
- Enrollment
- 40 enrolled
- Eligibility
- 18-65 years · All sexes
- Timeline
- 2024 – 2028
Study locations (3)
- Bellvitge University Hospital, L'Hospitalet de Llobregat, Barcelona, Spain
- Donostia University Hospital, Donostia / San Sebastian, Spain
- University Hospital 12 de Octubre, Madrid, Spain
Collaborators
Instituto de Salud Carlos III · Spanish Clinical Research Network - SCReN · Institut d'Investigació Biomèdica de Bellvitge
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06513533 on ClinicalTrials.gov